Ionis Pharmaceuticals (IONS) PT Raised to $64 at Needham & Company as ENDEAR Study Halted Early for Efficacy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Ionis Pharmaceuticals (IONS) PT Raised to $36 at Leerink Partners
August 1, 2016 3:30 PM EDTLeerink Partners analyst Michael Schmidt raised his price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $36.00 (from $26.00) after the company announced that nusinersen, its antisense drug in development for treatment of spinal muscular atrophy (SMA) met the primary endpoint at the interim analysis of the Ph III trial "ENDEAR", which is evaluating the drug's effect in infantile-onset Type I SMA.. The firm maintained an Market... More
Ionis Pharmaceuticals (IONS) PT Raised to $40 at BMO Capital
August 1, 2016 12:22 PM EDTBMO Capital analyst Do Kim raised his price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $40.00 (from $25.00) after positive interim data from the Phase III ENDEAR study for infant-onset SMA and Biogen exercising its option to license Nusinersen but maintained a Market Perform... More
Biogen (BIIB), Ionis (IONS) Announce Nusinersen Phase 3 Met Primary Endpoint in Infantile-Onset SMA
August 1, 2016 7:34 AM EDTBiogen (Nasdaq: BIIB) and Ionis Pharmaceuticals (Nasdaq: IONS) announced that nusinersen, their investigational treatment for spinal muscular atrophy (SMA), met the primary endpoint pre-specified for the interim analysis of ENDEAR, the Phase 3 trial evaluating nusinersen in infantile-onset (consistent with Type 1) SMA. The analysis found that infants receiving nusinersen experienced a statistically significant improvement in the achievement of motor milestones compared to those who did not receive treatment. Nusinersen demonstrated an acceptable safety profile in the trial. As a result of these findings, Biogen has exercised its option to develop... More
Ionis Pharma (IONS) Unit Receives EC Orphan Drug Designation Volanesorsen as FPL Treatment
July 28, 2016 4:01 PM EDTAkcea Therapeutics, a wholly-owned subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today that the European Commission (EC) has designated volanesorsen as an orphan medicinal product for the treatment of familial partial lipodystrophy (FPL). FPL is a rare lipid disorder characterized by abnormal fat distribution across the body and a range of metabolic abnormalities, including severe type 2 diabetes, high triglycerides, and accumulation of fat in the... More
